President and CEO
Mr. Stover has been Chief Executive Officer of Zebec Therapeutics LLC ("Zebec") since April 2014. Zebec is the successor to Quadrant Pharmaceuticals LLC, which Mr. Stover co-founded and was President and Director of from September 2013. Mr. Stover has been a Director and Chairman of the Audit Committee of PDI, Inc., a public company since 2005. From 2009 to February 2012, Mr. Stover served as the executive chairman of Targeted Nano Therapeutics LLC, a privately held biotechnology company focused on targeted delivery of peptides and proteins. Mr. Stover was also chairman of the audit committee and a member of the board of directors of Arbios Systems Inc. from 2005 to 2008 and a member of the board of directors of Influmedix, Inc. from 2010 to 2011.
From 2004 to 2008, he served as chief executive officer, president and director of Antares Pharma, Inc., a publicly held specialty pharmaceutical company listed on the American Stock Exchange. Prior to that, Mr. Stover was executive vice president and chief financial officer of Sicor, Inc., a publicly held company which manufactured and marketed injectable pharmaceutical products, and which was acquired by Teva Pharmaceutical Industries. Prior to that, Mr. Stover was executive vice president and director of a proprietary women's pharmaceutical company, Gynetics, Inc. ("Gynetics"), and before Gynetics, he was senior vice president and director of B. Braun Medical, Inc., a private global medical device and pharmaceutical company. For more than five years prior to that, Mr. Stover was a partner with PricewaterhouseCoopers (then Coopers and Lybrand), working in the lifesciences industry division. Mr. Stover received his B.A. in Accounting from Lehigh University and is a Certified Public Accountant.
Chief Commercial Officer
Greg Richard, Chief Commercial Officer at Interpace Diagnostics, has been in the healthcare business for over 25 years in various industries including managed care, biotech pharmaceuticals, CRO services, and diagnostics. He started his career in sales at Aetna and moved to Genentech as the Director of Managed Care. He transitioned in to the diagnostics industry as the Vice President of Managed Care for Quest Diagnostics and served in this role for 8 years. Greg also led the international clinical trials sales team while at Quest. Following his tenure at Quest, Greg worked for several privately held companies including CRO’s, molecular diagnostics, and anatomic pathology services providers. He also served as the Sr. Vice President of Sales for the Northeast Division of LabCorp. Greg is a certified Six Sigma Green Belt and frequent speaker at healthcare industry conferences such as the G2 Lab Institute and the NextGen Dx Summit.
Chief Financial Officer
In October 2016, Jim Early was appointed as the Chief Financial Officer of Interpace Diagnostics Group and as a consultant served as the Company’s principal financial officer, secretary and treasurer until becoming a permanent employee in March 2018. From August 2016 to October 2016 the Company had engaged Mr. Early as a consultant to perform the role of interim chief financial officer. From September 2015 to July 2016 Mr. Early served as the interim and subsequently permanent Chief Financial Officer of AbGenomics International Inc., a clinical stage drug development company with a product pipeline in immunology and oncology. From October 2014 to September 2015 Mr. Early served as the Chief Financial Officer of Zebec Therapeutics, LLC, a privately held specialty pharmaceutical company. In addition, Mr. Early has provided interim chief financial officer and business development services for pharmaceutical, life science and other similar companies as a sole proprietor from August 2009 to December 2013 and through Early Financial Consulting, LLC from January 2014 to March 2018.
Prior to his consulting role, Mr. Early was Senior Vice President of Finance and Administration and Corporate Secretary for Synageva BioPharma, an orphan drug development company and served as CFO for Anesthesiologists Associated, Inc., a revenue cycle management company serving the West Coast. Prior to these roles Mr. Early held several financial positions with Zila Pharmaceuticals, an oral health specialty pharmaceutical company, and served as a financial analyst for Schein Pharmaceutical. Mr. Early is a Certified Public Accountant, having served on the audit staff of Coopers and Lybrand, now PwC, and has an MBA in Finance and Accounting from the UCLA-Anderson School of Management and a BBA in Accounting from the University of Notre Dame.
Chief Scientific Officer
Dr. Finkelstein is a board certified pathologist specializing in gastrointestinal pathology with extensive experience in molecular diagnostics. He is the Adjunct Professor of Pathology, Drexel University on the faculty of Allegheny General Hospital, Pittsburgh, PA. He is the founder of RedPath Integrated Pathology, which was acquired by Interpace Diagnostics in 2014.
Sara A. Jackson
VP of Clinical Development
Sara Jackson has 15 years of experience in biomedical research and development. She has been an integral part of both the research and development and medical affairs teams for a variety of pharmaceutical and diagnostics companies, translating biomedical research into viable commercial products. Under Dr. Jackson’s leadership, the clinical development team has conducted various clinical validity and utility studies to support the use of PathFinderTG assays in clinical practice. Their efforts continue to bring new assays to market. Dr. Jackson earned a PhD in biochemistry and molecular genetics from the University of Pittsburgh School of Medicine and completed her postdoctoral research fellowship with the Centers for Disease Control and Prevention. She has co-authored numerous publications and presented at various national and international scientific conferences.
SVP of Operations
Glenn has nearly 30 years of biotechnology industry experience. He has worked for a wide range of companies in roles of increasing responsibility. These roles have included leadership and functional expertise in Quality Assurance, Regulatory Affairs, Customer Service, R&D, Product Development, and Laboratory Operations.
Christina M. Narick, MD
VP of Pathology
As the Vice President of Pathology for Interpace Diagnostics, Dr. Narick provides interpretation and diagnosis of both cytology and molecular cases in Interpace Diagnostics’ state-of-the-art, CLIA-certified, and CAP-accredited laboratory. Dr. Narick is a board-certified anatomic and clinical pathologist and completed her fellowship in cytopathology at Allegheny General Hospital under the direction of Dr. Jan Silverman, a leading authority in cytopathology. Dr. Narick earned her medical and undergraduate degrees from West Virginia University and an MBA from Portland State University. Prior to entering the medical field, Dr. Narick worked in process engineering, quality systems, and operations management in the manufacturing arena.